Impressive clinical results speak for themselves. For patients with advanced pancreatic cancer, traditional chemotherapy only delivers a median overall survival of 6.7 months. Treated with Daraxonrasib, the figure doubled to 13.2 months, cutting the death risk by 60%. This breakthrough brings a promising new targeted therapy against this deadly malignancy.

Keeping pace with the latest research, Chemscene has launched a full lineup of innovative structural building blocks. Many items are available at kilogram scale.

Explore our portfolio: www.arctomsci.com/store/chemscene

Product inquiry: [email protected]